Xencor designs engineered antibodies using its XmAb protein-engineering platform for cancer and autoimmune disease. The company advances proprietary candidates and licenses platform technologies and molecules to larger pharmaceutical partners, generating collaboration and royalty-style economics. Bispecific and Fc-engineered formats are a technical hallmark of its approach. Its model blends internal clinical development with partnered programs rather than a single commercial franchise.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 32.7 | — | -48.4 | — |
| Q2 2025 | 43.6 | — | -30.8 | — |
| Q3 2025 | 21 | — | -6 | — |
| Q4 2025 | 28.2 | — | -6.7 | — |
| Q1 2026 | 4.5 | -86.2% | -128.9 | — |
| Q2 2026 | 51.2 | 17.5% | -21.7 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Septerna, Inc. (SEPN), Trevi Therapeutics, Inc. (TRVI), Schrödinger, Inc. (SDGR), UroGen Pharma Ltd. (URGN), Vir Biotechnology, Inc. (VIR), Braveheart Bio, Inc. (BRVE)